Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Percentage of Participants with a Reduction from Baseline in the 24-hour Cough Frequency by ≥ 30%, 50% and 70%

Assessed using an ambulatory cough monitor

Time frame: Week 4

Change from Baseline in Leicester Cough Questionnaire (LCQ)

The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the effect of cough on 3 main domains: physical, psychological and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life.

Time frame: Week 4

Change from baseline in cough severity

Assessed by Cough Severity Visual Analogue Scale \[VAS\] by the participant on a 100 mm visual analog scale where higher scores indicate worse severity.

Time frame: Week 4

Incidence (% of subjects) of treatment-emergent adverse events (TEAEs)

Time frame: 2 Weeks after the last study medication intake

Severity (mild, moderate, or severe) of treatment-emergent adverse events (TEAEs)

Time frame: 2 Weeks after the last study medication intake